Update shared on 06 Nov 2025
Fair value Decreased 3.46%Narrative Update on Jamjoom Pharmaceuticals Factory
Analysts have revised their price target for Jamjoom Pharmaceuticals Factory down from SAR178.41 to SAR172.24. This change reflects updated expectations around discount rates and future profitability.
What's in the News
- The board meeting is scheduled for October 23, 2025, to discuss financial results for Q3 2025 (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has decreased from SAR178.41 to SAR172.24.
- Discount Rate has risen slightly, from 18.98% to 19.11%.
- Revenue Growth forecast has increased, moving from 12.84% to 13.50%.
- Net Profit Margin expectation has improved from 30.62% to 31.04%.
- Future P/E multiple has declined from 33.18x to 30.83x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.